We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+35.5%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$614M
AUM Growth
+$229M
Cap. Flow
+$94.5M
Cap. Flow %
15.38%
Top 10 Hldgs %
48.42%
Holding
129
New
38
Increased
24
Reduced
19
Closed
23

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$12.3M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$9.48M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.95M
4
AZN icon
AstraZeneca
AZN
+$6.54M
5
NICE icon
Nice
NICE
+$5.73M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$50.1M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.3M
3
GILD icon
Gilead Sciences
GILD
+$6.5M
4
GSK icon
GSK
GSK
+$6.39M
5
AGN
Allergan plc
AGN
+$6.11M

Sector Composition

Rank Sector Weight
1 Healthcare 57.48%
2 Technology 4.42%
3 Communication Services 1.38%
4 Industrials 1.09%
5 Consumer Discretionary 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNTK icon
1
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
$106M 17.27%
+1,600,000
New +$91.9M
OEF icon
2
PUT
iShares S&P 100 ETF
OEF
$20.1B
$60.4M 9.84%
220,500
+218,500
+10,925% +$21M
MRK icon
3
Merck
MRK
$322B
$18.7M 3.05%
314,400
+209,600
+200% +$12.3M
TEVA icon
4
Teva Pharmaceuticals
TEVA
$40.8B
$18.5M 3.01%
402,000
-198,200
-33% -$10.3M
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.57B
$16.2M 2.63%
+263,047
New +$7.95M
AGN
6
DELISTED
Allergan plc
AGN
$16.1M 2.62%
70,000
-25,000
-26% -$6.11M
LLY icon
7
Eli Lilly
LLY
$1.02T
$16.1M 2.61%
200,000
– –
BIIB icon
8
Biogen
BIIB
$30B
$15.7M 2.55%
50,000
-500
-1% -$148K
CLCD
9
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$15.3M 2.48%
400,000
-100,137
-20% -$1.48M
PFE icon
10
Pfizer
PFE
$143B
$14.4M 2.35%
449,649
– –
ITRN icon
11
Ituran Location and Control
ITRN
$1.09B
$12.1M 1.97%
456,668
-3,784
-0.8% -$93.2K
CELG
12
DELISTED
Celgene Corp
CELG
$11.5M 1.87%
110,000
-45,000
-29% -$4.87M
AMGN icon
13
Amgen
AMGN
$208B
$11M 1.79%
65,900
-19,100
-22% -$3.23M
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$9.7M 1.58%
535,000
+485,000
+970% +$9.48M
GILD icon
15
Gilead Sciences
GILD
$162B
$8.92M 1.45%
112,700
-80,000
-42% -$6.5M
ALXN
16
DELISTED
Alexion Pharmaceuticals
ALXN
$8.58M 1.4%
70,000
+27,677
+65% +$3.56M
VTRS icon
17
Viatris
VTRS
$20.4B
$7.62M 1.24%
200,000
-50,000
-20% -$2.22M
BMRN icon
18
CALL
BioMarin Pharmaceuticals
BMRN
$11.6B
$7.4M 1.21%
+80,000
New +$7.53M
SAGE
19
DELISTED
Sage Therapeutics
SAGE
$7.34M 1.2%
159,500
+90,000
+129% +$3.66M
FOLD
20
DELISTED
Amicus Therapeutics
FOLD
$6.7M 1.09%
905,000
-100,000
-10% -$675K
AZN icon
21
AstraZeneca
AZN
$263B
$6.57M 1.07%
+100,000
New +$6.54M
AKAO
22
DELISTED
Achaogen Inc
AKAO
$6.23M 1.01%
1,300,313
+42,947
+3% +$171K
ARRY
23
DELISTED
Array Biopharma Inc
ARRY
$6.08M 0.99%
+900,000
New +$3.48M
NICE icon
24
Nice
NICE
$5.79B
$5.76M 0.94%
+86,040
New +$5.73M
CRVS icon
25
Corvus Pharmaceuticals
CRVS
$1.12B
$5.35M 0.87%
325,053
– –
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sphera Funds Management held 129 positions worth $614M, up 59% from $385M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sphera Funds Management deployed $94.5M of net new capital in Q3 2016, opening 38 new positions and adding to 24 existing holdings. Its largest new stake was Sarepta Therapeutics: 263,047 shares worth $16.2M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 77% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Shire pic, an estimated $50.1M trimmed.

  • Sphera Funds Management's largest Q3 2016 buy was Sarepta Therapeutics: 263,047 shares worth $16.2M.
  • Sphera Funds Management added most to Merck in Q3 2016, an estimated $12.3M increase.
  • Sphera Funds Management's biggest Q3 2016 reduction was Shire pic, cutting an estimated $50.1M.
  • Sphera Funds Management fully exited GSK in Q3 2016, selling an estimated $6.39M.
  • Sphera Funds Management's ten largest holdings make up 48% of its $614M portfolio in Q3 2016.
  • Sphera Funds Management opened 38 new positions and closed 23 in Q3 2016.
  • Sphera Funds Management's portfolio value rose 59% quarter-over-quarter to $614M.

Based on Sphera Funds Management's 13F filing for Q3 2016, filed 14 Nov 2016.